RT Journal Article
SR Electronic
T1 Epidemiological feature, viral shedding, and antibody seroconversion among asymptomatic SARS-CoV-2 carriers and symptomatic/presymptomatic COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.18.20248447
DO 10.1101/2020.12.18.20248447
A1 Chen, Yi
A1 Li, Ping
A1 Ding, Yi-Bo
A1 Liu, Miao
A1 Liu, Lei-Jie
A1 Yi, Bo
A1 Wu, Ting
A1 Dong, Hong-Jun
A1 Lao, Xu-Ying
A1 Ding, Ke-Qing
A1 Wang, Hai-Bo
A1 Zhang, Dong-Liang
A1 Tan, Xiao-Jie
A1 Wang, Zhong-Fa
A1 Xu, Guo-Zhang
A1 Cao, Guang-Wen
YR 2020
UL http://medrxiv.org/content/early/2020/12/20/2020.12.18.20248447.abstract
AB Novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is pandemic. However, data concerning the epidemiological features, viral shedding, and antibody dynamics between asymptomatic SARS-CoV-2 carriers and COVID-19 patients remain controversial. We enrolled 193 subjects infected with SARS-CoV-2 in Ningbo and Zhoushan, Zhejiang, China from January 21 to March 6, 2020. All subjects were followed up to monitor the dynamics of immunoglobulin M (IgM) and IgG against SARS-CoV-2. Of those, 31 were asymptomatic carriers, 149 were symptomatic patients, and 14 were presymptomatic patients. Compared to symptomatic patients, asymptomatic carriers were younger and had higher levels of white blood cell and lymphocyte, lower levels of C-reactive protein and viral load, and shorter viral shedding duration. Conversion of IgM from positive to negative was shorter in asymptomatic carriers than in COVID-19 patients (P=0.030). The proportion of those persistently seropositive for IgG was higher in COVID-19 patients than in asymptomatic carriers (P=0.037). Viral load was higher in symptomatic than presymptomatic patients. Viral shedding was longer in presymptomatic patients than in asymptomatic carriers. Conclusively, asymptomatic carriers have a higher antiviral immunity to clear SARS-CoV-2 than do symptomatic patients and this antiviral immunity is not contributable to humoral immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from National Natural Science Foundation of China (82041022), Science and Technology Commission Shanghai Municipality (No. 20JC1410200; 20431900404), Science and Technology Bureau of Putuo district, Zhoushan Municipality (No. 2020GY306), and Ningbo Science and Technology Major Project (2020C50001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Commission of Ningbo CDC and Putuo CDC.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analyzed during the current study are available from the corresponding author on reasonable request.